Phynova to advance PYN6 to clinical stage
UK-listed Phynova, a developer of botanical drugs, will advance its preclinical candidate PYN6, for the topical prevention and treatment of methicillin-resistant Staphylococcus aureus, to clinical stages.
Recently-completed preclinical studies suggest the compound shows strong results in its inhibitory effects on the growth of the bacterium and its bactericidal action. Furthermore, trials suggest that MRSA cultured in the presence of PYN6 does not become resistant to the agent and it retains its action in gel formulations. As a consequence, Phynova has selected PYN6 as its next clinical candidate, targeting the first human studies within 12 to 15 months.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze